(Alliance News) - Scancell Holdings PLC on Wednesday said it plans to begin a Phase 1/2 trial for its cancer treatment Modi-1 in the first half of 2021.
The cancer immunotherapy treatment firm said the study for Modi-1 will include patients with solid tumours such as triple negative breast cancer, ovarian cancer, renal cancer, and head and neck cancer.
Scancell noted successful completion of GMP drug substance manufacture for all three of the conjugates that make up the Modi-1 product, adding that technical challenges previously faced in relation to one of the peptide components have now been successfully resolved. This allows progression to GMP drug product manufacture and formulation of clinical supplies in the third quarter of 2020.
The trial announcement comes amid the company's publication of a peer-reviewed research paper in the Journal for ImmunoTherapy of Cancer which described Modi-1’s ability to stimulate potent T cell responses that translate into tumour protection in melanoma and ovarian cancer models.
"These data further validate the unique mode of action, and long-term protection, of citrullinated Moditope peptides and their potential as novel immunotherapies for hard to treat cancers, particularly when conjugated with the AMPLIVANT adjuvant to boost the overall immune response," said Scancell Chief Scientific Officer Lindy Durrant.
The stock was trading 9.7% higher at 6.25 pence each on Wednesday afternoon in London, but 12% lower than at the start of the year.
By Ife Taiwo; ifetaiwo@alliancenews.com.
Copyright 2020 Alliance News Limited. All Rights Reserved.
Scancell Holdings (SCLP)